Granite Asia sees lab testing as bottleneck in AI-driven drug discovery

• Laboratory testing is becoming the bottleneck in AI-driven drug discovery, shifting competitive advantage toward reliable experimental validation rather than molecule design alone.
• Earendil Labs says AI design and high-throughput biology can prepare molecules for manufacturing and toxicology studies within one year, versus about three.
• BioMap uses customers’ historical experimental data to build task-specific models, positioning its platform beyond individual drug-development pipelines.
• Earendil CEO Peng Jian estimates autonomous self-improving models in life sciences remain three to five years away, with data accumulation still underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Granite Asia Capital Pte Ltd. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.